Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.51 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1993886 | 0.90 | CYP4F2 (0.56) | NPC1RAB9ACYP4F2CYP4A11TP53 | |
| SCHEMBL4193217 | 0.88 | TP53 (0.61) | CYP4F2CYP4A11TP53POLBHPGD | |
| SCHEMBL27542212 | 0.87 | NPC1 (0.52) | NPC1RAB9ACYP4F2CYP4A11TP53 | |
| SCHEMBL8873010 | 0.87 | CYP4F2 (0.56) | NPC1RAB9ACYP4F2CYP4A11TP53 | |
| SCHEMBL29617015 | 0.86 | TP53 (0.62) | NPC1RAB9ACYP4F2CYP4A11TP53 | |
| SCHEMBL8873024 | 0.86 | NPC1 (0.55) | NPC1RAB9ACYP4F2CYP4A11TP53 | |
| SCHEMBL4726691 | 0.86 | BCL2 (0.56) | CYP4F2CYP4A11SMN1; SMN2 | |
| SCHEMBL259 | 0.85 | CA12 (0.59) | CYP4F2CYP4A11 | |
| SCHEMBL5863231 | 0.85 | TP53 (0.56) | CYP4F2CYP4A11TP53POLBHPGD | |
| SCHEMBL5863191 | 0.85 | CA12 (0.58) | NPC1RAB9ACYP4F2CYP4A11HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7132456-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2006-11-07 | — | — | US | disclosed |
| US-20060052449-A1 | Novel mch receptor antagonists | ELI LILLY AND COMPANY | 2006-03-09 | — | — | US | disclosed |
| EP-1572637-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-14 | — | — | EP | disclosed |
| WO-2004052848-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2004-06-24 | — | — | WO | disclosed |
| US-5700938-A | Intermediates for imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1997-12-23 | — | — | US | disclosed |
| US-5618969-A | Intermediates for imidazopyridines | EISAI CO., LTD. (JP) | 1997-04-08 | — | — | US | disclosed |
| US-5608068-A | Process for the preparation of imidazopyridine derivatives and intermediates | EISAI CO., LTD. (JP) | 1997-03-04 | — | — | US | disclosed |
| US-5587504-A | Sulfonyloxy-biphenylcarboxylic ester derivatives which are intermediates | EISAI CO., LTD. (JP) | 1996-12-24 | — | — | US | disclosed |
| US-5583229-A | Process for the preparation of imidazopyridine derivatives | EISAI CO., LTD. (JP) | 1996-12-10 | — | — | US | disclosed |
| US-5559236-A | Intermediates for substituted biphenylmethylmidazopyridine angiotensin II antagonists | EISAI CO., LTD. (JP) | 1996-09-24 | — | — | US | disclosed |
| US-5557002-A | Process for the preparation of biphenyl containing intermediates useful in making angiotensin II receptor antagonists | EISAI CO., LTD. (JP) | 1996-09-17 | — | — | US | disclosed |
| US-5554757-A | Process for the preparation of imidazopyridine derivatives, and intermediates therefore | EISAI CO., LTD. (JP) | 1996-09-10 | — | — | US | disclosed |
| EP-0627433-A1 | PROCESS FOR PRODUCING IMIDAZOPYRIDINE DERIVATIVE AND INTERMEDIATE | Eisai Co., Ltd. (JP) | 1994-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060052449-A1 | Novel mch receptor antagonists | MCHR1, MCHR2, MC1R | NPC1 698/4885RAB9A 996/4885CYP4F2 3158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.